DGKA and cancer: It demonstrated its prevalent inhibitory activity against the sole DGKα (IC50 value of 15 μM reported) in a dose‐dependent manner, even if growing doses are able to affect the activity also of other isoforms, and therefore its repurposing for cancer treatment was proposed.